Trust Signals
Written by the FormBlends Medical Team. Reviewed against FDA drug databases, PubMed, USP monographs, and WADA prohibited lists current as of May 2026. No compound with the exact name "albutyrol" appears in any of these authoritative sources. This page explains why that matters and what you are most likely searching for.Key Takeaways
- "Albutyrol" does not exist as a named compound in FDA, PubMed, USP, or WADA databases as of 2026. It is almost certainly a misspelling of albuterol or a phonetic mashup with butyrate.
- Albuterol (salbutamol) is a prescription bronchodilator drug, a beta-2 adrenergic agonist with molecular weight roughly 239 daltons. It is not a supplement and not a peptide by any pharmacological definition.
- Butyrate compounds (sodium butyrate, tributyrin) are dietary supplements derived from a short-chain fatty acid. They share no mechanism, structure, or regulatory category with albuterol.
- WADA prohibits systemic albuterol in competitive sport but allows inhaled doses up to 1600 mcg per day, a distinction that matters for athletes searching performance-enhancement information.
- Any product sold commercially as "albutyrol supplement" should be treated as either mislabeled, adulterated, or fraudulent until proven otherwise by a third-party certificate of analysis.
Direct Answer: Is Albutyrol a Supplement, Drug, or Peptide? (40-60 words)
"Albutyrol" as a standalone compound does not exist in authoritative scientific or regulatory records. The word is almost certainly a misspelling of albuterol, which is an FDA-approved prescription drug and not a supplement or peptide. If you encountered this term on a supplement label, treat that product as unverified until a credentialed COA confirms exactly what it contains.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is "albutyrol" and does it exist?
- How is albuterol actually classified?
- Is albuterol or albutyrol a peptide?
- What is the mechanism of albuterol, with real numbers?
- Evidence ledger: what does the science actually support?
- What most pages get wrong about this compound
- Could "albutyrol" mean a butyrate supplement?
- Honest head-to-head: albuterol vs clenbuterol vs butyrate
- Operational and label literacy: how to evaluate any product claiming this name
- What are the real risks of albuterol outside prescription use?
- Frequently Asked Questions
- Sources
What is "albutyrol" and does it actually exist?
A search of the FDA's National Drug Code directory, PubMed, the USP compendium, and the WADA prohibited substance list returns zero results for a compound named "albutyrol." The same is true of the Chemical Abstracts Service registry and the NIH PubChem database as of this writing.
The most probable explanations for the search term, in order of likelihood:
- Misspelling of albuterol. Albuterol is one of the most commonly prescribed drugs in the world. Phonetically, "albutyrol" is close enough that autocomplete and voice search frequently produce it. This is the overwhelmingly most likely origin of the query.
- Phonetic blend of albuterol and butyrate. Butyrate supplements (sodium butyrate, tributyrin) are sold widely. Someone seeing both names in fitness forums could blend them into "albutyrol."
- A marketed supplement using a non-standard invented name. Some supplement companies create trade names that echo drug names to imply efficacy. If you have a product in hand with this name, see the label literacy section below.
How is albuterol actually classified?
Albuterol (international nonproprietary name: salbutamol) is a short-acting beta-2 adrenergic agonist (SABA). Its regulatory classifications are unambiguous:
| Jurisdiction | Classification | Prescription required? |
|---|---|---|
| United States (FDA) | Prescription drug, New Drug Application approved. Listed in FDA Orange Book. | Yes |
| European Union (EMA) | Medicinal product (salbutamol). Prescription required in most member states. | Yes (generally) |
| WADA (sport) | Prohibited in-competition (systemic routes). Inhaled permitted up to 1600 mcg per 24 hours. | N/A (TUE required above threshold) |
| Dietary supplement (US, DSHEA) | Not eligible. Approved drugs cannot be marketed as supplements under 21 USC 321(ff). | N/A |
The DSHEA point is important. Under the Dietary Supplement Health and Education Act of 1994, a substance that has been approved as a drug or investigated as a drug in a clinical trial that was publicly disclosed cannot be sold as a dietary supplement. Albuterol was approved by FDA decades before DSHEA. It is categorically ineligible for supplement status regardless of dose or route.
Is albuterol or "albutyrol" a peptide?
No, on both counts. A peptide is a molecule composed of two or more amino acids joined by peptide bonds. Albuterol is a catecholamine derivative, specifically a phenethylamine with a tertiary butyl group on the amine nitrogen. Its molecular formula is C13H21NO3 and its molecular weight is approximately 239 daltons. It contains no amino acid residues, no peptide bond, and no structural feature that qualifies it as a peptide under any pharmacological, chemical, or regulatory definition.
The confusion may also arise because some performance-enhancing compounds are peptides (for example, IGF-1 LR3, BPC-157, TB-500) and some are small molecules (for example, albuterol, clenbuterol, GW501516). These are distinct pharmacological categories. Calling albuterol a peptide is the equivalent of calling ibuprofen a hormone.
What is the mechanism of albuterol, with real numbers?
Albuterol binds selectively to beta-2 adrenergic receptors (ADRB2), which are G-protein-coupled receptors expressed in airway smooth muscle, skeletal muscle, adipose tissue, and the heart (though beta-1 selectivity dominates in cardiac tissue). The sequence of events:
- Albuterol binds ADRB2, stimulating the Gs alpha subunit to activate adenylyl cyclase.
- Adenylyl cyclase converts ATP to cyclic AMP (cAMP). Intracellular cAMP rises rapidly, typically within minutes at therapeutic doses.
- In airway smooth muscle, elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light-chain kinase, reducing its activity and causing smooth muscle relaxation. This is the bronchodilation mechanism. Onset of action by inhalation is 5 to 15 minutes.
- In skeletal muscle, the same cAMP-PKA pathway has been shown in animal studies and limited human trials to promote protein synthesis and reduce proteolysis, though the effect magnitude in humans is substantially smaller than in rodent models.
- In adipose tissue, cAMP activates hormone-sensitive lipase, promoting lipolysis. This is the mechanism behind albuterol's off-label use in fat loss contexts.
Pharmacokinetic specifics (inhaled route, from FDA label data): Plasma half-life is approximately 3 to 8 hours. Bioavailability by inhalation is low, estimated at 10 to 20% of the metered dose reaching systemic circulation, because most drug deposits in the oropharynx and is swallowed. Peak plasma concentrations after a standard 2.5 mg nebulized dose are in the range of 2 to 3 nanograms per milliliter.
What this mechanism does NOT prove: Elevated cAMP in skeletal muscle does not automatically translate to meaningful lean mass gains in healthy humans. Animal studies use doses far exceeding any safe human inhaled dose. The human anabolic data (discussed in the evidence ledger) shows modest, inconsistent effects. The mechanistic pathway exists; the clinical magnitude is uncertain and dose-dependent in a range that overlaps with significant cardiovascular risk.
Evidence Ledger: What Does the Science Actually Support?
| Claim | Best evidence type | Effect direction | Confidence | Key caveat |
|---|---|---|---|---|
| Albuterol is effective for acute bronchospasm in asthma | Multiple large human RCTs, meta-analyses, FDA approval | Strong positive | HIGH | None material; this is established medicine |
| Systemic albuterol promotes lean mass in humans | Small human RCTs (Caruso et al. and others, n typically under 30) | Weak to modest positive | LOW | Small samples, non-athlete populations, doses exceeding safe inhaled range |
| Inhaled albuterol (at permitted WADA doses) provides meaningful ergogenic benefit | Systematic review (Pluim et al., Br J Sports Med 2011); human trials | Minimal to none in non-asthmatic athletes | MODERATE | Benefit appears largely confined to individuals with underlying airway obstruction |
| Albuterol promotes fat loss via lipolysis in humans | Mechanistic (cAMP-HSL pathway) plus animal data; limited human data | Direction plausible, magnitude unclear | VERY LOW | Human studies at doses producing significant lipolysis also produce tachycardia and hypokalemia |
| "Albutyrol" as a named compound has any evidence base | No data; compound not found in scientific literature | No direction (no compound) | VERY LOW / NOT APPLICABLE | Cannot grade evidence for a compound that does not appear in the literature |
| Sodium butyrate improves gut barrier function | Human trials (small), animal models, mechanistic data | Modest positive in IBD and gut permeability contexts | LOW to MODERATE | Most human trials small; optimal dose and form not established |
What Most Pages Get Wrong About This Topic
Most supplement blogs and question-answer sites do one of three things with the "albutyrol" query:
- They autocorrect silently to albuterol and then describe albuterol as if "albutyrol" is an alternate name. It is not an alternate name. It may be a misspelling, but presenting the two as synonymous misleads readers into thinking a supplement category exists when it does not.
- They describe albuterol's anabolic mechanism as if it translates directly to real-world muscle-building. The cAMP pathway is real. The human anabolic data is not robust. Studies showing muscle effects used oral or intravenous albuterol at doses well above any inhaled clinical range, and samples were small. A skeptical clinician would not recommend albuterol for muscle building based on current evidence.
- They omit the DSHEA ineligibility point entirely. Because albuterol is an approved drug, it cannot be sold as a supplement by law. Any product labeled "albutyrol supplement" is either mislabeled or contains something different from albuterol. Both scenarios are a consumer safety issue.
Could "Albutyrol" Mean a Butyrate Supplement?
Butyrate is a short-chain fatty acid (SCFA), specifically a four-carbon saturated fatty acid (butanoic acid, CAS 107-92-6). It is produced naturally by colonic fermentation of dietary fiber and is sold as sodium butyrate or as tributyrin (a prodrug form that may improve delivery past the stomach).
Butyrate is:
- A dietary supplement under DSHEA in the U.S.
- Not a peptide (no amino acid structure)
- Not a drug (no NDA or ANDA on file for dietary supplement uses)
- Structurally and mechanistically unrelated to albuterol
Butyrate's primary studied mechanisms include histone deacetylase (HDAC) inhibition, which affects gene expression in colonocytes, and energy substrate provision for intestinal epithelial cells. These mechanisms have nothing in common with beta-2 adrenergic agonism. If someone searching "albutyrol supplement" is actually looking for butyrate, they are searching for a completely different category of compound with different evidence, different risks, and different legal status.
Honest Head-to-Head: Albuterol vs Clenbuterol vs Butyrate
| Feature | Albuterol (salbutamol) | Clenbuterol | Sodium butyrate |
|---|---|---|---|
| Compound class | Beta-2 agonist, small molecule | Beta-2 agonist, small molecule | Short-chain fatty acid, supplement |
| Supplement legal status (US) | Not eligible (approved drug) | Not eligible (drug) | Legal dietary supplement |
| Prescription required (US) | Yes | Not approved for human use in US; unapproved drug | No |
| Plasma half-life | Roughly 3 to 8 hours | Roughly 35 hours (long; source: Zimmer 1976 cited in WADA reviews) | Very short; butyrate is rapidly oxidized in colonocytes |
| WADA status | Prohibited (systemic); inhaled permitted to 1600 mcg/day | Prohibited (all routes) | Not prohibited |
| Human anabolic evidence quality | Low (small trials, high doses) | Very low (mostly animal; unapproved in humans) | Not applicable (no anabolic claim) |
| Primary legitimate medical use | Asthma, COPD bronchospasm | Veterinary bronchodilator; not approved for human use in US | Investigational gut health, IBD support |
| Where albuterol/clenbuterol lose vs butyrate | Cardiovascular risk at off-label doses, legal barriers, drug-drug interactions, WADA consequences | Butyrate wins on safety profile and legal accessibility, but loses on any claimed anabolic effect (none established) | |
Operational and Label Literacy: How to Evaluate Any Product Claiming This Name
If you have a product in hand that uses the name "albutyrol," apply this checklist before use:
- Demand a full ingredient list with CAS numbers. Every ingredient must have a verifiable CAS number. "Albutyrol" has no CAS number. If the label cannot map to a real CAS-registered compound, the product cannot be verified.
- Request a certificate of analysis (COA) from an ISO 17025-accredited third-party laboratory. The COA must show identity testing (not just purity), performed by HPLC, LC-MS/MS, or equivalent. A COA from the manufacturer's own lab does not count as independent verification.
- Search the FDA Tainted Products Database. FDA maintains a list of supplements found to contain undisclosed drug ingredients. Beta-2 agonists including albuterol have appeared in tainted supplement products. The search is free at FDA.gov.
- Check the NIH Dietary Supplement Label Database (DSLD). If the product is registered there, its label is on file. If not registered, that absence is a caution sign for a U.S.-marketed supplement.
- Understand what degraded albuterol looks like. Albuterol solutions exposed to air oxidize and turn yellow to brown. A discolored inhalation solution is a sign of degradation. This is not relevant to solid supplements, but matters if you obtain albuterol solution from a compounding pharmacy.
What Are the Real Risks of Albuterol Outside Prescription Use?
At prescribed inhaled doses for asthma (typically 90 to 180 mcg per actuation, up to 4 times daily), albuterol's systemic exposure is low and side effects are generally mild: tremor, mild tachycardia, mild decrease in serum potassium. These are documented in the FDA-approved prescribing information.
At higher systemic doses (oral tablets, intravenous, or very high inhaled doses), the risk profile changes meaningfully:
- Hypokalemia: Beta-2 stimulation drives potassium into cells. At supratherapeutic doses, serum potassium can fall to levels associated with cardiac arrhythmia. This is not a theoretical risk; it is documented in albuterol overdose case reports.
- QT prolongation and arrhythmia: Clinically significant at high systemic doses, particularly in individuals with underlying cardiac disease or concurrent use of QT-prolonging drugs.
- Tachycardia and palpitations: Common at supratherapeutic doses; physiologically expected given catecholamine pathway activation.
- Tolerance and tachyphylaxis: Prolonged beta-2 agonism downregulates ADRB2 receptor expression, reducing efficacy over time. This is documented in asthma management literature and is a reason why continuous use without medical supervision is ill-advised.
Frequently Asked Questions
Is albutyrol a supplement, a drug, or a peptide?
"Albutyrol" as a standalone compound does not exist in authoritative scientific or regulatory records. The word is almost certainly a misspelling of albuterol, which is an FDA-approved prescription drug and not a supplement or peptide. If you encountered this term on a supplement label, treat that product as unverified until a credentialed COA confirms exactly what it contains.
What is albuterol classified as?
Albuterol (salbutamol) is classified as a short-acting beta-2 adrenergic agonist (SABA). It is an FDA-approved prescription drug used for bronchospasm in asthma and COPD. It is neither a peptide nor a dietary supplement under U.S. law.
Could "albutyrol" refer to a butyrate compound or supplement?
Possibly. The "-butyrol" suffix may confuse searchers who are thinking of butyrate (sodium butyrate or tributyrin), which is a short-chain fatty acid sold as a dietary supplement. Butyrate is not a peptide and not a drug. It is a distinct compound from albuterol entirely.
Is albuterol used as a performance-enhancing drug?
Albuterol has anabolic and fat-mobilizing properties at systemic doses above those used for inhalation. WADA prohibits systemic albuterol but permits inhaled doses up to 1600 mcg per day. Some studies show modest lean mass increases, but evidence in healthy non-asthmatic athletes is limited and effect sizes are small.
Is albuterol a peptide?
No. Albuterol is a small-molecule catecholamine derivative with molecular weight approximately 239 daltons. A peptide, by definition, is a chain of amino acids. Albuterol contains no amino acid structure and is not classified as a peptide by any pharmacological standard.
Can you buy albuterol as a supplement in the United States?
No. Albuterol is a prescription drug in the U.S. It cannot legally be sold as a dietary supplement. Any product marketed as a supplement containing albuterol would be an adulterated or misbranded product under FDA rules.
What is the mechanism of albuterol?
Albuterol selectively binds beta-2 adrenergic receptors, activating adenylyl cyclase and raising intracellular cyclic AMP. In airway smooth muscle this causes relaxation. At systemic doses, elevated cAMP also activates protein kinase A pathways that may promote muscle protein synthesis and lipolysis.
What are the risks of using albuterol for non-medical purposes?
Systemic albuterol causes tachycardia, hypokalemia, tremor, and QT prolongation at higher doses. Chronic off-label use without medical supervision carries cardiovascular risk. WADA bans systemic use in competitive sport. These risks are absent or minimal at prescribed inhaled doses for asthma.
How does albuterol compare to clenbuterol as a performance compound?
Clenbuterol is a longer-acting beta-2 agonist with a plasma half-life of roughly 35 hours vs albuterol's 3 to 8 hours. Clenbuterol shows stronger anabolic and lipolytic effects in animal models, but its long half-life makes adverse event management harder. Neither is approved for performance use in humans.
Why do people search for "albutyrol supplement"?
The search likely reflects confusion between albuterol (the drug), butyrate supplements, and possibly bodybuilding marketing that blurs drug and supplement categories. No legitimate supplement named "albutyrol" exists in FDA or NIH databases as of 2026.
What should I do if I found a product labeled "albutyrol"?
Treat it with high caution. No compound by this exact name has an established safety or efficacy record. It may be a misspelling of albuterol (a prescription drug) or an unapproved novel compound. Consult a licensed clinician and check FDA's MedWatch and supplement adulteration databases before use.
Is butyrate (sodium butyrate) a supplement or a drug?
Sodium butyrate is sold as a dietary supplement in the U.S. It is a short-chain fatty acid, not a drug and not a peptide. Evidence for gut health benefits is mostly preclinical; human RCT data for most claimed benefits is limited and preliminary.
Sources
- U.S. Food and Drug Administration. Albuterol Sulfate Inhalation Solution prescribing information. FDA Orange Book. Reviewed and updated through 2025. Available at: FDA.gov/drugs.
- World Anti-Doping Agency. Prohibited List 2024. WADA-AMA.org. Section S3: Beta-2 Agonists. Accessed May 2026.
- Pluim BM, de Hon O, Staal JB, et al. Beta-2 Agonists and Physical Performance: A Systematic Review and Meta-analysis of Randomized Controlled Trials. British Journal of Sports Medicine. 2011;45(1):16-23.
- Dietary Supplement Health and Education Act of 1994 (DSHEA). 21 U.S.C. 321(ff). U.S. Congress.
- National Institutes of Health. PubChem Compound Database. CID for salbutamol (albuterol): 2083. Accessed May 2026. pubchem.ncbi.nlm.nih.gov.
- U.S. Food and Drug Administration. Tainted Products Marketed as Dietary Supplements. FDA.gov/food/dietary-supplements. Accessed May 2026.
- Caruso JF, Signorile JF, Perry AC, et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Medicine and Science in Sports and Exercise. 1995;27(11):1471-1476.
- National Institutes of Health. Dietary Supplement Label Database (DSLD). dsld.od.nih.gov. Accessed May 2026.
- Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology. 2011;17(12):1519-1528.
- Billington CK, Penn RB, Hall IP. Beta2 Agonists. Handbook of Experimental Pharmacology. 2017;237:23-40.